Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Advances in Nanoparticle Delivery for Cancer Immunotherapy
share announcement

Advances in Nanoparticle Delivery for Cancer Immunotherapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 6613

Special Issue Editors

Prof. Dr. Ninh La-Beck

E-Mail Website
Guest Editor
Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79430, USA
Interests: nanomedicine; liposomes; immunopharmacology; immunotherapy; immunotoxicology; tumor immunology
Prof. Dr. Xinli Liu

E-Mail Website
Guest Editor
Department of Pharmacological and Pharmaceutical Sciences, Chollege of Pharmacy, University of Houston, 77204 Houston, TX, USA
Interests: nanomedicine; lipid nanoparticles; cancer pharmacology; drug conjugates; vaccine

Special Issue Information

Dear Colleagues,

Nanoparticles encompass a heterogeneous group of engineered drugs and drug carriers that have tremendous therapeutic potential in the treatment of cancer by enabling temporal and spatial control of drug delivery. However, nanoparticle platforms significantly increase interactions with immune cells and immune proteins compared to non-nanoparticle formulations. These interactions were historically viewed as undesirable for the delivery of cytotoxic chemotherapies targeted at proliferating tumor cells. The discovery and clinical success of immune checkpoint inhibitors and dendritic and T cell therapies in cancer validates immune modulation as a therapeutic modality in eradicating cancer. In this light, the interaction between nanoparticles and the immune system are an untapped opportunity to target immunotherapies to tumors and a modality for tunable pharmackinetics of syngergistic combination immunotherapy. Nanoparticles designed to target immune cells by modulating the innate and adaptive immunity instead of directly targeting tumor cells also provide new opportunities for nanoparticles in cancer immunotherapy.

This Special Issue highlights the current progress and landscape of nanoparticle delivery for cancer immunotherapy. We invite articles on all aspects of drug formulation and development, pharmacokinetics and pharmacodynamics, and cellular/molecular mechanisms at the crossroads of nanotechnology and cancer immunotherapy.

Prof. Dr. Ninh La-Beck
Prof. Dr. Xinli Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • liposomes
  • immunotherapy
  • tumor immunology

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 4428 KiB  
Article
Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes
by Alberto Gabizon, Hilary Shmeeda, Benjamin Draper, Ana Parente-Pereira, John Maher, Amaia Carrascal-Miniño, Rafael T. M. de Rosales and Ninh M. La-Beck
Pharmaceutics 2023, 15(11), 2606; https://doi.org/10.3390/pharmaceutics15112606 - 9 Nov 2023
Viewed by 1456
Abstract
Encapsulation of Doxorubicin (Dox), a potent cytotoxic agent and immunogenic cell death inducer, in pegylated (Stealth) liposomes, is well known to have major pharmacologic advantages over treatment with free Dox. Reformulation of alendronate (Ald), a potent amino-bisphosphonate, by encapsulation in pegylated liposomes, results [...] Read more.
Encapsulation of Doxorubicin (Dox), a potent cytotoxic agent and immunogenic cell death inducer, in pegylated (Stealth) liposomes, is well known to have major pharmacologic advantages over treatment with free Dox. Reformulation of alendronate (Ald), a potent amino-bisphosphonate, by encapsulation in pegylated liposomes, results in significant immune modulatory effects through interaction with tumor-associated macrophages and activation of a subset of gamma-delta T lymphocytes. We present here recent findings of our research work with a formulation of Dox and Ald co-encapsulated in pegylated liposomes (PLAD) and discuss its pharmacological properties vis-à-vis free Dox and the current clinical formulation of pegylated liposomal Dox. PLAD is a robust formulation with high and reproducible remote loading of Dox and high stability in plasma. Results of biodistribution studies, imaging with radionuclide-labeled liposomes, and therapeutic studies as a single agent and in combination with immune checkpoint inhibitors or gamma-delta T lymphocytes suggest that PLAD is a unique product with distinct tumor microenvironmental interactions and distinct pharmacologic properties when compared with free Dox and the clinical formulation of pegylated liposomal Dox. These results underscore the potential added value of PLAD for chemo-immunotherapy of cancer and the relevance of the co-encapsulation approach in nanomedicine. Full article
(This article belongs to the Special Issue Advances in Nanoparticle Delivery for Cancer Immunotherapy)
►▼ Show Figures

Graphical abstract

26 pages, 5884 KiB  
Article
Doxorubicin-Loaded Polymeric Micelles Conjugated with CKR- and EVQ-FLT3 Peptides for Cytotoxicity in Leukemic Stem Cells
by Fah Chueahongthong, Singkome Tima, Sawitree Chiampanichayakul, Pornngarm Dejkriengkraikul, Siriporn Okonogi, Mathurada Sasarom, Soraya Rodwattanagul, Cory Berkland and Songyot Anuchapreeda
Pharmaceutics 2022, 14(10), 2115; https://doi.org/10.3390/pharmaceutics14102115 - 4 Oct 2022
Cited by 1 | Viewed by 1503
Abstract
Doxorubicin (Dox) is the standard chemotherapeutic agent for acute myeloblastic leukemia (AML) treatment. However, 40% of Dox-treated AML cases relapsed due to the presence of leukemic stem cells (LSCs). Thus, poloxamer 407 and CKR- and EVQ-FLT3 peptides were used to formulate Dox-micelles (DMs) [...] Read more.
Doxorubicin (Dox) is the standard chemotherapeutic agent for acute myeloblastic leukemia (AML) treatment. However, 40% of Dox-treated AML cases relapsed due to the presence of leukemic stem cells (LSCs). Thus, poloxamer 407 and CKR- and EVQ-FLT3 peptides were used to formulate Dox-micelles (DMs) and DM conjugated with peptides (CKR and EVQ) for improving AML-LSC treatment. Results indicated that DMs with a weight ratio of Dox to P407 of 1:200 had a particle size of 23.3 ± 1.3 nm with a high percentage of Dox entrapment. They were able to prolong drug release and maintain physicochemical stability. Following effective DM preparation, P407 was modified and conjugated with FLT3 peptides, CKR and EVQ to formulate DM-CKR, DM-EVQ, and DM-CKR+DM-EVQ. Freshly synthesized DMs displaying FLT3 peptides showed particle sizes smaller than 50 nm and a high drug entrapment level, comparable with DMs. DM-CKR+DM-EVQ was considerably more toxic to KG-1a (AML LSC-like cell model) than Dox-HCl. These FLT3-targeted DMs could increase drug uptake and induce apoptosis induction. Due to an increase in micelle-LSC binding and uptake, DMs displaying both peptides tended to improve the potency of Dox compared to a single peptide-coupled micelle. Full article
(This article belongs to the Special Issue Advances in Nanoparticle Delivery for Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

33 pages, 6655 KiB  
Review
Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy
by Huiqun Huang, Ronghui Liu, Jie Yang, Jing Dai, Shuhao Fan, Jiang Pi, Yubo Wei and Xinrong Guo
Pharmaceutics 2023, 15(7), 1868; https://doi.org/10.3390/pharmaceutics15071868 - 2 Jul 2023
Cited by 11 | Viewed by 3169
Abstract
Cancer immunotherapy is an innovative treatment strategy to enhance the ability of the immune system to recognize and eliminate cancer cells. However, dose limitations, low response rates, and adverse immune events pose significant challenges. To address these limitations, gold nanoparticles (AuNPs) have been [...] Read more.
Cancer immunotherapy is an innovative treatment strategy to enhance the ability of the immune system to recognize and eliminate cancer cells. However, dose limitations, low response rates, and adverse immune events pose significant challenges. To address these limitations, gold nanoparticles (AuNPs) have been explored as immunotherapeutic drug carriers owing to their stability, surface versatility, and excellent optical properties. This review provides an overview of the advanced synthesis routes for AuNPs and their utilization as drug carriers to improve precision therapies. The review also emphasises various aspects of AuNP-based immunotherapy, including drug loading, targeting strategies, and drug release mechanisms. The application of AuNPs combined with cancer immunotherapy and their therapeutic efficacy are briefly discussed. Overall, we aimed to provide a recent understanding of the advances, challenges, and prospects of AuNPs for anticancer applications. Full article
(This article belongs to the Special Issue Advances in Nanoparticle Delivery for Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop